Eris Lifesciences · NSE: ERIS · BSE: 540596
Q2 FY20 results · Jul–Sep 2019
Eris Lifesciences reported revenue from operations of ₹284.79 crore (up 7.8% from Q2 FY19) and net profit of ₹92.71 crore (up 8.4% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 284.79 | 264.18 | +7.8% | 274.30 | +3.8% |
| Other income | 5.17 | 6.15 | −16.0% | 2.83 | +82.9% |
| Total income | 289.96 | 270.34 | +7.3% | 277.13 | +4.6% |
| Profit before tax | 102.77 | 92.31 | +11.3% | 94.92 | +8.3% |
| Net profit for the period | 92.71 | 85.51 | +8.4% | 84.06 | +10.3% |
| EPS, basic (₹) | 6.74 | 6.20 | +8.7% | 6.11 | +10.3% |
| Net margin (%) | 32.6 | 32.4 | 30.6 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 272.90 | 240.81 | +13.3% | 262.33 | +4.0% |
| Other income | 4.90 | 6.24 | −21.4% | 2.72 | +80.5% |
| Total income | 277.80 | 247.05 | +12.4% | 265.04 | +4.8% |
| Profit before tax | 101.33 | 89.99 | +12.6% | 92.04 | +10.1% |
| Net profit for the period | 91.53 | 83.98 | +9.0% | 81.96 | +11.7% |
| EPS, basic (₹) | 6.66 | 6.10 | +9.2% | 5.96 | +11.7% |
| Net margin (%) | 33.5 | 34.9 | 31.2 |
Consolidated
- Filed with BSE
- 07 Nov 2019, 17:49 IST
- Board meeting
- 07 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Nov 2019, 17:49 IST
- Board meeting
- 07 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE